- In early June 2026, Waters Corporation expanded its analytical portfolio with multiple high-performance launches, including new BioResolve and GTxResolve columns and next-generation Xevo MRT P10 and Cyclic IMS P20 mass spectrometers for complex biopharmaceutical and multiomics applications.
- A key aspect is Waters’ push deeper into biologics and structural omics, offering ready-to-use, higher-sensitivity platforms that aim to simplify impurity analysis, imaging, and large-cohort research workflows for pharmaceutical and translational labs.
- We’ll now examine how Waters’ push into higher-sensitivity multiomics and impurity analysis platforms may influence its existing investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Waters Investment Narrative Recap
To own Waters, you need to believe its move into advanced multiomics, biologics and diagnostics can support earnings growth while it integrates BD’s Biosciences and Diagnostic Solutions assets and manages weak pharma and ANG capital budgets. The June instrument and column launches strengthen the product story, but do not materially change the near term integration risk or sensitivity to customer spending, which remain the key swing factors for the stock today.
Among the recent announcements, the FDA 510(k) clearance for the BD BACTEC FXI Culture System looks most relevant, because it ties the Waters story directly to high throughput clinical diagnostics and underscores how success or setbacks in absorbing BD’s diagnostic portfolio could influence whether expected revenue synergies and margin gains are fully realized.
Yet beneath Waters’ impressive new product cycle, investors should be aware of how integration risk around the BD deal could...
Read the full narrative on Waters (it's free!)
Waters' narrative projects $7.5 billion revenue and $1.4 billion earnings by 2029. This requires 33.5% yearly revenue growth and a roughly $760 million earnings increase from $642.6 million today.
Uncover how Waters' forecasts yield a $393.14 fair value, a 10% upside to its current price.
Exploring Other Perspectives
These launches arrive as the most cautious analysts were already assuming US$7.6 billion of revenue and US$1.4 billion of earnings by 2029, highlighting how views on Waters’ reliance on mature platforms and emerging market exposure can differ sharply from the more optimistic consensus.
Explore 3 other fair value estimates on Waters - why the stock might be worth just $393.14!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Waters research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Waters research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Waters' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com